CTRI/2020/07/026419尚未招募3 期
A Randomized, Multi-Centric, Double Blind, Double Dummy, Active Controlled, Parallel, Comparative Study to Evaluate Efficacy and Safety of Fixed Dose Combination of Silodosin and Solifenacin Capsules in Comparison to Silodosin Capsules in Male Patients Having Benign Prostatic Hyperplasia (BPH)/ Lower Urinary Tract Symptoms (LUTS) with Over Active Bladder (OAB)
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male patient, aged between 50 to 75 years (both inclusive), having Benign Prostatic Hyperplasia (BPH)/ Lower Urinary Tract Symptoms (LUTS) and with residual Over Active Bladder (OAB) symptoms despite treatment with Silodosin 8 mg or other alpha blockers (Alfuzosin 10 mg, Tamsulosin 0.4 mg) for more than equal to 4 weeks prior to screening
- •2.Patient with total IPSS more than equal to 13 with urgency item score more than 1 during screening
- •3.Patient with IPSS-QoL item score of greater than 2 during screening
- •4.Patient with number of micturitions more than equal to 8 times per 24 hours and at least 2 urgency episodes per 24 hours in a 3 day bladder diary during screening
- •5.Patient with Post Void Residual (PVR) volume less than equal to 150 ml and maximum urinary flow rate (Qmax) between 5 to 15 mL/s during screening
- •6.Patient is willing to give informed consent
- •7.Patient must agree to use adequate contraception from study entry till the last dose of the study medication.
排除标准
- •1)Patient taking anti-muscarinics (other than Solifenacin), antispasmodics, any substances to influence voiding function at the time of screening or planning to take during study
- •2)Patient with history of prostate cancer and/or previous prostatic/ bladder neck surgery
- •3)Patient with history of urethral obstruction due to stricture, valves, sclerosis or tumour and patient with previous urethral surgery
- •4)Patient with autonomic neuropathy, neurologic bladder conditions (e.g. multiple sclerosis, spinal cord injury, Parkinson disease)
- •5)Patient with clinically significant bladder outflow obstruction other than BPH, as judged by investigatorPatients receiving Miconazole.
- •6)Patient with chronic inflammation, bladder stones, bladder neck stricture, sclerosis, severe vesical diverticulum, urethral stricture
- •7)Patient with history of cancer or undergoing chemotherapy
- •8)Patient with history of severe cardiac diseases, including angina requiring certain treatment with nitrates or any clinically significant conditions
- •9)Patient with a history of esophageal or intestinal or gastric pylorus obstruction or gastrointestinal disorders (including gastric retention and toxic megacolon) which is associated with decreased gastrointestinal motility at the time of screening
- •10)Patient with hiatus hernia/gastro-oesophageal reflux and/or who is concurrently taking medicinal products (such as bisphosphonates) that can cause or exacerbate oesophagitis
- •11)Patient with irradiation to the pelvis, interstitial cystitis, prostatitis
- •12)Patient who is likely to require catheterization within next 3 months
- •13)Patient with history of symptomatic orthostatic hypotension or recurrent dizziness, vertigo, loss of consciousness or syncope
- •14)Patient with history of any condition that is a contraindication for anticholinergic treatment including narrow angle glaucoma, urinary retention and myasthenia gravis
- •15)Patient who started with a 5-alpha reductase inhibitor within 3 months prior to screening or planning to take during the study
- •16)Patient undergoing haemodialysis
- •17)Patient with symptomatic acute Urinary Tract Infection (UTI) during the screening period or recurrent UTI (more than equal to 2 episodes within the last 6 months from the screening)
- •18)Patient with moderate to severe renal impairment (Creatinine clearance less than 50 mL/min) and severe hepatic impairment (AST and ALT more than 3 x ULN)
- •19)Patient with serum Prostate Specific Antigen (PSA) beyond 4 ng/ ml at screening
- •20)Patient with uncontrolled hypertension (BP more than equal to 140/90 mm of Hg) and type 2 diabetes (HbA1c more than 9%)
- •21)Patient has a clinically significant disorder that, in the opinion of the investigator, would result in the patientâ??s inability to understand and comply with the requirements of the study
- •22)Patient with history of HIV and/or Hepatitis B and/or Hepatitis C
- •23)Patient with history of angioedema with airway obstruction
- •24)Patient with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
- •25)Patient planning cataract surgery during the study
- •26)Patients having history of QT prolongation or patients who are taking medications known to prolong QT interval
- •27)Patient using any nitrates, androgens, estrogens, lu
研究者
相似试验
已完成
3 期
Study to evaluate safety and efficacy of Silodosin and Tadalafil Capsules in Comparison to Tadalafil Tablets for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia and Erectile DysfunctioCTRI/2021/12/038380Sun Pharmaceutical Industries Limited376
尚未招募
3 期
A Multicentric Randomized Double Blind Double Dummy Parallel Group Comparative Phase III Clinical Study to Evaluate the Efficacy Safety and Tolerability in subjects with Uncontrolled Essential Hypertension with stable Coronary Artery Disease (CAD).CTRI/2022/11/047055Ajanta Pharma Limited
招募中
3 期
Diabetic Peripheral Pain Coexisting with Vitamin B12 deficiency to treat with FDC of Pregabalin plus Methylcobalamin plus Duloxetine (Delayed Release) Capsules.CTRI/2024/01/062147Ravenbhel Healthcare Pvt. Ltd.
尚未招募
3 期
A clinical study to assess the efficacy and safety of Pregabalin, Duloxetine and Mecobalamin Capsules in neuropathic pain patients.CTRI/2024/03/063691Synokem Pharmaceuticals Ltd
尚未招募
不适用
Study to Evaluate the Efficacy and Safety of Wound Healing Topical Spray in Patients withDiabetic Foot Ulcer.CTRI/2022/04/041672Inzpera Healthsciences Limited